Compare Recursion Pharmaceuticals Inc (RXRX) vs Snap On Incorporated (SNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Snap On Incorporated — how do they compare? Recursion Pharmaceuticals Inc trades at $3.36 (market cap $1.78B), while Snap On Incorporated trades at $412.41 (market cap $21.27B). The key difference: Snap On Incorporated is far larger — about 11.9× Recursion Pharmaceuticals Inc's market cap, and Snap On Incorporated pays a 2.37% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | SNA | |
|---|---|---|
Market Cap | $1.78B | $21.27B |
Sector | Health | Technology |
52-Week High | $6.79 | $419.31 |
52-Week Low | $2.84 | $321.38 |
Enterprise Value | $1.30B | $20.90B |
Dividend Yield | — | 2.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.
Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.
Snap-on Incorporated (SNA) trades at $416.35, up 0.4% on the day, with a bullish technical outlook supported by moving averages and strong support near $413. The company reported Q2 2026 earnings of $4.96 per share, beating estimates, with organic sales growth of 3% driven by tools and diagnostics. Recent acquisitions like Diesel Laptops for $100 million expand its heavy-duty diagnostics reach, while solid cash flow and a 19.6% net income margin underscore operational strength.
SNA offers a compelling investment case with robust profitability, strategic growth initiatives, and a consensus price target of $455.33 implying 9.4% upside. Risks include integration costs from acquisitions, premium valuation multiples, and potential macroeconomic pressures on automotive demand. Analyst sentiment is positive with 65% buy ratings, but execution on growth initiatives remains key to justifying current valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Snap On Incorporated
Snap-on Incorporated is a leading global innovator, manufacturer, and marketer of tools, equipment, diagnostics, repair information, and systems solutions for professional users. Its products are widely used in vehicle service and repair, as well as in other demanding industrial environments. The company is best known for its premium tool brand, often sold through a network of franchised mobile stores, and is a primary supplier to technicians in the transportation industry.
Read more on SNA →
